Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1045 + mRNA-1230
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1045 and mRNA-1230 are two distinct investigational mRNA-based combination vaccine candidates developed by Moderna to provide consolidated protection against major seasonal respiratory viruses. mRNA-1045 is a bivalent vaccine candidate targeting seasonal influenza (incorporating quadrivalent influenza antigens) and respiratory syncytial virus (RSV). mRNA-1230 is a trivalent vaccine candidate that expands this coverage to include SARS-CoV-2 (COVID-19). Both vaccines utilize Moderna's proprietary lipid nanoparticle (LNP) technology to deliver mRNA sequences encoding viral surface proteins—specifically hemagglutinin for influenza, the prefusion F protein for RSV, and the spike protein for SARS-CoV-2—to elicit robust humoral and cellular immune responses. These candidates are currently being evaluated in Phase 1 clinical trials, primarily focusing on safety and immunogenicity in older adults (aged 50-75 years) to streamline immunization schedules for respiratory pathogens.
- Other names
- mRNA-1045mRNA1045mRNA 1045mRNA-1230mRNA1230mRNA 1230
02
Targets
SARS-CoV-2 spikeRSV F (Respiratory syncytial virus fusion protein)HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-1045 + mRNA-1230.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1045 + mRNA-1230.